Paradoxical inflammation induced by anti-TNF agents in patients with IBD. (Q38023146)

27 August 2017

title

Paradoxical inflammation induced by anti-TNF agents in patients with IBD. (English)

1 reference

27 August 2017

0 references

0 references

0 references

2

1 reference

27 August 2017

1

Isabelle Cleynen

1 reference

27 August 2017

language of work or name

English

0 references

publication date

3 July 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

27 August 2017

published in

1 reference

27 August 2017

volume

9

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

496-503

1 reference

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tumour necrosis factor inhibitors in ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

TNFalpha therapy in psoriatic arthritis and psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Adalimumab safety in global clinical trials of patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Guttate psoriasis induced by infliximab in a child with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Occurrence of plantar pustular psoriasis during treatment with infliximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Infliximab-induced psoriaform rash

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Infliximab‐induced Psoriasis in Children With Inflammatory Bowel Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriasis induced by infliximab in a patient suffering from Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Palmoplantar and scalp psoriasis occurring during anti–tumour necrosis factor-α therapy: a case series of four patients and guidelines for management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Repeated Paradoxical Aggravation of Preexisting Psoriasis during Infliximab Treatment for Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Onset of flexural psoriasis during infliximab treatment for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriasiform and pustular eruption induced by infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriasiform eruption induced by infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tailoring the length of antiviral treatment for hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Psoriatic Alopecia/Alopecia Areata–Like Reactions Secondary to Anti–Tumor Necrosis Factor-α Therapy: A Novel Cause of Noncicatricial Alopecia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata following adalimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata during anti-TNF alpha therapy: Nine cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata during etanercept therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Alopecia areata universalis elicited during treatment with adalimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Cutaneous vasculitis induced by TNF inhibitors: a report of three cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Vasculitis induced by tumor necrosis factor-targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Refractory multisystem sarcoidosis responding to infliximab therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Detailed genetic characterization of the interleukin-23 receptor in psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Variants in the 5q31 cytokine gene cluster are associated with psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Filaggrin mutations in children with severe atopic dermatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Recent developments in the understanding of antinuclear autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

The role of Tumor Necrosis Factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Development of psoriasis after B cell depletion with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Efalizumab‐induced guttate psoriasis. Successful management and re‐treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Atopic dermatitis: new insights and opportunities for therapeutic intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.125

Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients

31 March 2020

1 reference

12 December 2020

Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series

1 reference

12 December 2020

Induction of pustular lesions during infliximab therapy for Crohn's disease

1 reference

12 December 2020

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

1 reference

12 December 2020

Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions

1 reference

12 December 2020

The status of biologic therapies in the treatment of moderate to severe psoriasis

1 reference

12 December 2020

Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab

1 reference

12 December 2020

Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy

1 reference

12 December 2020

Development of sarcoidosis during anti-TNF-alpha treatment: what is the mechanism?

1 reference

12 December 2020

Infliximab associated new-onset psoriasis

1 reference

12 December 2020

Anti-TNF agents for the treatment of psoriasis.

1 reference

12 December 2020

Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study

1 reference

12 December 2020

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab

1 reference

12 December 2020

Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease

1 reference

12 December 2020

Psoriatic skin lesions induced by certolizumab pegol

1 reference

12 December 2020

10.1038/NRGASTRO.2012.125

Identifiers

DOI

1 reference

27 August 2017

1 reference